VEGFR1/Flt-1 Antibody (Y103)

Product Discontinued

VEGFR1/Flt-1 Antibody (Y103) Summary

• Immunogen: A synthetic peptide corresponding to residues in N-terminus of human VEGFR1 was used as immunogen.
• Marker: Endothelial Cell Marker
• Specificity: The antibody can detect both VEGFR1 and its splice isoform sFlt1.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: FLT1
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:1000
  • Immunocytochemistry/ Immunofluorescence 1:250
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Frozen 1:250
  • Immunohistochemistry-Paraffin 1:250
  • Immunoprecipitation 1:100
  • Simple Western
  • Western Blot 1:500-1000
• Application Notes: In Western blot this antibody detects a band at approximately 180 kDa. Use in Immunohistochemistry-Frozen reported in scientific literature (PMID 24647000)

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 49% PBS, 0.05% BSA and 50% Glycerol
• Preservative: 0.01% Sodium Azide
• Purity: Protein A or G purified

Notes

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Alternate Names for VEGFR1/Flt-1 Antibody (Y103)

• EC 2.7.10
• EC 2.7.10.1
• FLT
• FLT1
• Flt-1
• Fms-like tyrosine kinase 1
• fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor)
• FRT
• Tyrosine-protein kinase FRT
• Tyrosine-protein kinase receptor FLT
• vascular endothelial growth factor receptor 1
• Vascular permeability factor receptor
• VEGF R1
• VEGFR1
• VEGFR-1

Background

VEGFR-1 (vascular endothelial growth factor receptor 1) is a 180-kDa membrane receptor tyrosine kinase that is the receptor for vascular endothelial growth factor (VEGF), VEGFB and PGF. VEGF is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions (1). VEGFR-1 has seven extracellular Ig-like domains; the second domain from the N-terminus is necessary and sufficient for high affinity VEGF binding (2). The biological effects of VEGF are mediated by VEGFR-1 and VEGFR-2 (1), and two major tyrosine phosphorylation sites at Tyr 1213 and Tyr 1242 and two minor tyrosine phosphorylation sites at Tyr 1327 and Tyr 1333 exist in VEGFR-1 (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR1/Flt-1 Antibody (NB110-57643)(11)

Publications using NB110-57643

• Mansour, SG;Zhang, WR;Moledina, D;Coca, SG;Jia, Y;Thiessen-Philbrook, H;McArthur, E;Inoue, K;Koyner, JL;Shlipak, MG;Wilson, FP;Garg, AX;Ishibe, S;Parikh, CR;, ; The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery Am. J. Kidney Dis. 2019-04-05 [PMID: 30955944] (ICC/IF, Human)
• Gibbins KJ, Gibson-Corley KN, Brown AS et al. Effects of excess thromboxane A2 on placental development and nutrient transporters in a Mus musculus model of fetal growth restriction Biol. Reprod. 2018-01-17 [PMID: 29351577] (Mouse)
• Iinuma H, Fukushima R, Inaba T et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med 2014-04-11 [PMID: 24708624] (IHC-P, Human)
• Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 2014-03-20 [PMID: 24647000] (IHC-Fr, Mouse)
• Frank NY, Schatton T, Kim S et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011-02-01 [PMID: 21212411]
• Yu L, Baxter PA, Voicu H et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo . Neuro Oncol 12 580-594. 2010-01-01 [PMID: 20511191] (IF/IHC)
• Kosugi T, Nakayama T, Li Q et al. Soluble-Flt-1 Gene Therapy Ameliorates Albuminuria, but Accelerates Tubulointerstitial Injury in Diabetic Mice . Am J Physiol Renal Physiol. 2009-01-01 [PMID: 20015944]
• Sato W, Kosugi T, Zhang L et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy . Laboratory Investigation 88 949-961. 2008-01-01 [PMID: 18607348] (WB, IF/IHC)
• Cimpean AM, Raica M, Encicab S et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus . Ann Anat 190 238-245. 2008-01-01 [PMID: 18356031] (IF/IHC)
• Herring A, Yasin H, Ambree O et al. Environmental Enrichment Counteracts Alzheimer’s Neurovascular Dysfunction in TgCRND8 Mice . Brain Pathology 18 32-39. 2008-01-01 [PMID: 17924982] (WB, IF/IHC)
• Amura CR, Brodsky KS, Groff R et al. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/- ) mice . Am J Physiol Cell Physiol 293 C419-C428. 2007-01-01 [PMID: 17475663] (WB)

Bioinformatics

• Gene Symbol: FLT1
• Entrez:
  • 2321(Human)
  • 14254(Mouse)
  • 54251(Rat)
• Uniprot:
  • P17948()